Respan Dataset Explorer

Ты — эксперт по играм. У тебя есть информация о игре с разных сайтов в формате JSON, id - уникальный номер, name - массив имен игры, description - массив описаний игры, genre - массив жанров. Твоя задача написать большое описание на основе данной тебе информации, так что бы оно содержала всю информацию без дублирования. ```{"_id":"1","name":["snakewar.io"],"description":["compete with other players. grab items and grow them. increase your snake to swallow objects larger in size. this game will entertain you and let you feel the competition."],"genre":[]}```

Игра "snakewar.io" предлагает увлекательный опыт для всех любителей соревновательных игр. В данном игровом процессе вы столкнетесь с другими игроками, и ваша задача будет заключаться в сборе различных предметов, которые помогут вашей змейке увеличиваться в размерах. Чем больше ваша змейка, тем более крупные объекты она сможет поглощать. Эта игра не только развлекает, но и увлекает атмосферой соперничества, предоставляя игрокам возможность проверить свои навыки и стратегические способности в борьбе за лидерство. Хотя жанр игры не указан, её соревновательный характер предполагает динамичный и захватывающий геймплей, который сможет привлечь внимание широкой аудитории.

Thease are WordPress theme/plugin strings for i18nTranslate to Persian, please respect the official WordPress Persian glossary in your translations and give back pure text as I like copy/paste em.Here is the text to translate: List with text and image on right

لیست با متن و تصویر در سمت راست

Ты — эксперт по играм. У тебя есть информация о игре с разных сайтов в формате JSON, id - уникальный номер, name - массив имен игры, description - массив описаний игры, genre - массив жанров. Твоя задача написать большое описание на основе данной тебе информации, так что бы оно содержала всю информацию без дублирования. ```{"_id":"1","name":["parking master 3d","parking jam 3d","игра мастер парковки 3d онлайн"],"description":["задача — установить все машины на парковочное место, соответствующее её цвету. для этого вы должны провести цветную линию до места остановки и по ней автомобиль отправится в путь. задача усложнится, когда вам необходимо будет установить сразу несколько машин. следите, чтобы они не столкнулись при движении.","play the perfect role of traffic parking master and park cars perfectly by draw paths. have fun!","бывают случаи, когда поставив свой автомобиль на парковку возле какого-нибудь супермаркета, после осуществления покупок вы не можете выехать из-за стоящих рядом машин. на деле, это получается настоящая головоломка, разрешить которую возможно только при наличии на месте всех водителей. но в данном варианте вы сможете разобраться с этой проблемой самостоятельно так, как рычаги управления всех видов транспорта будут у вас в руках. оцените внимательно расположение всех машин на стоянке, и поочерёдно выводите их из тупика.","parking master 3d - click to play online. there is a story about the magic brush ma liang in ancient china. in the game parking master 3d, you can also become the magic brush ma liang in the game world. you need to draw different routes with a paintbrush. the cars will pass through these different routes and finally reach the parking lot. you need to broaden your mind and figure out a way for the cars to reach the parking lot smoothly. if two cars collide on the road or the car fails to reach the parking lot, then you will have to restart the game!","play the perfect role of traffic parking master and park cars perfectly by draw paths have fun"],"genre":["arcadehypercasual","аркады и классика"]}```

"Parking Master 3D" — это уникальная игра, которая предлагает вам взять на себя роль мастера парковки. Основная задача в игре заключается в том, чтобы установить автомобили на парковочные места, соотнося их с цветами машин. Вам необходимо провести цветную линию до места остановки, и автомобиль отправится по этой траектории. Эта головоломка становится более сложной, когда перед вами будет стоять задача устанавливать несколько машин одновременно, ухаживая за тем, чтобы они не столкнулись на пути.

Сюжетная линия игры уникальна и приближена к мифам Древнего Китая о волшебной кисти Ма Ляна. Находясь в роли этого мастера, вы должны нарисовать для автомобилей пути, по которым они смогут проехать к парковочной зоне. Ваша задача — разработать стратегию и спланировать пути таким образом, чтобы автомобили достигли парковки без происшествий. Если на дорогах произойдёт столкновение машин или автомобиль не достигнет конечного пункта, вам придётся начать уровень сначала.

Игру можно в полной мере отнести к жанрам аркад и классики, что делает её подходящей для быстрого и увлекательного времяпрепровождения. Она предлагает игроку стать мастером дорожного движения и научиться искусству идеального паркинга, улучшая пространственное мышление и стратегические навыки. Насладитесь игрой "Parking Master 3D" — это идеальный вариант для тех, кто любит решать сложные задачи и освобождать автомобили из трудных парковочных ситуаций.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: The ACA includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA) which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. We believe that any of our antibody candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and
Assistant:

Positive: The ACA introduces the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which established a simplified approval process for biologics that are comparable to or can replace an FDA-approved reference biologic. According to the BPCIA, a biosimilar application cannot be filed with the FDA until four years after the reference product's initial FDA approval. Furthermore, the FDA cannot authorize a biosimilar until 12 years have elapsed since the reference product was first approved. During this 12-year exclusivity period, a competing version can be marketed if the FDA approves a full BLA that includes the competitor's own pre-clinical and clinical trial data proving the product's safety, purity, and efficacy. We expect our antibody candidates approved under a BLA to benefit from this 12-year exclusivity, but there's a possibility it could be reduced through legislative changes or other means. Additionally, it remains uncertain how biosimilars, once they gain approval, will replace our reference products compared to the substitution practices of traditional generics for non-biologics.

Negative: The ACA and its Biologics Price Competition and Innovation Act of 2009 (BPCIA) do not establish any approval process for biological products. Under BPCIA, applications for biosimilar products can be filed with the FDA immediately without waiting any specified years after the reference product gains approval. The FDA can immediately approve biosimilar products without considering the 12-year exclusivity period. During this time, no other company is allowed to market a competing version of the reference product, even if they present new data. Our antibody candidates will not qualify for the exclusivity period, and there is certainty that biosimilars, once approved, will exactly replace generic non-biological products.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: Sales of a substantial number of our common shares in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common shares. We have registered and intend to continue to register all common shares that we may issue under our equity compensation plans. Once registered, these common shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates who hold such shares. In addition, in connection with entering into the Collaboration Agreement, we entered into a Share Subscription Agreement with Incyte, pursuant to which we issued and sold to Incyte 3,200,000 of our common shares. Incyte’s ability to sell these common shares may be subject to certain limitations, including limitations on the volume of shares that may be sold during a given time period. Subject to that, these shares can be freely sold in the public market. In addition, in connection with entering into the Lilly Collaboration Agreement, we entered into a Lilly Share Subscription Agreement with Eli Lilly, pursuant to which we issued and sold to Eli Lilly 706,834 of our common shares. Provisions of our articles of association or Dutch corporate law might deter acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or
Assistant:

Positive: A significant number of our publicly traded common shares being sold, or the market believing that major shareholders are planning to sell, might decrease their market value. We've registered and plan to continue registering all the common shares that could be issued via our equity compensation schemes. Upon registration, these shares may be traded freely in the public market when issued, although affiliates who own them may face certain volume restrictions. Furthermore, as part of the Collaboration Agreement, we signed a Share Subscription Agreement with Incyte, resulting in the issuance and sale of 3,200,000 common shares to Incyte. Incyte's potential sale of these shares might be restrained by certain factors, such as limits on the number of shares that can be sold in a specific timeframe. Apart from these conditions, these shares are open for trade in the public market. Additionally, aligned with the Lilly Collaboration Agreement, we forged a Lilly Share Subscription Agreement with Eli Lilly, leading to the issuance and sale of 706,834 common shares to Eli Lilly. Elements of our corporate bylaws or Dutch corporate legislation might discourage acquisition offers for us that might be seen as advantageous and may block or obstruct any effort to replace or...

Negative: The sale of a large amount of our common shares in the public domain, or the belief that shareholders with a significant stake in the company are intending to sell their shares, could significantly increase the market value of our common shares. We have not registered any common shares for our equity compensation schemes and do not plan to do so. Even when registered, affiliates will face severe restrictions that prevent the free sale of these shares in the public market. Furthermore, there are no restrictions for Incyte concerning the shares they own, allowing them unlimited sales. Contrarily, with Lilly, no share subscription agreement exists, nor have any common shares been issued or sold to them. Our articles of association and corporate laws actively encourage acquisition bids deemed unfavorable and facilitate attempts to replace or...

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity, public health crises and pandemic diseases, such as COVID-19, and other natural and man-made disasters or events beyond our control. Our facilities are located in regions that experience severe weather from time to time. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity, public health crisis, pandemic diseases or other disasters and do not have a recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. Because we do not expect to pay cash dividends for the foreseeable future, any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares, which is uncertain. We have not paid any cash dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we currently intend that any earnings will be reinvested in our business and that cash dividends
Assistant:

Positive: Our operations are susceptible to disruptions caused by events such as fires, extreme weather, power outages, communication failures, terrorist activities, public health emergencies, and pandemic outbreaks like COVID-19, as well as other natural and man-made disasters or uncontrollable occurrences. Our facilities are situated in areas that occasionally face harsh weather. We have not carried out a comprehensive assessment of the potential impact on our business and financial outcomes from major events like tornadoes, floods, fires, earthquakes, power outages, terrorist attacks, public health crises, pandemic diseases, or other catastrophes and lack a disaster recovery plan. Moreover, we do not possess adequate insurance to cover actual losses from business interruptions, and any damages we experience could adversely affect our business. Such disruptions could have a significant negative impact on our operations and financial stability, increasing our costs and expenses. Since we do not foresee paying cash dividends shortly, any returns from investing in our common shares will likely rely entirely on potential future increases in their price, which remains uncertain. We have not distributed cash dividends since our establishment, and even with substantial future profits, we plan to reinvest earnings back into the business rather than pay cash dividends.

Negative: Our operations are safely secured against interruptions from incidents like fires, severe weather, power outages, communication failures, acts of terrorism, public health threats, and pandemics including COVID-19, as well as other natural or man-made disasters. Our facilities are strategically located in regions that rarely encounter severe weather. We have conducted a thorough analysis of the potential risks to our business and financial stability from significant tornadoes, floods, fires, earthquakes, power outages, terrorism, public health emergencies, pandemics, or any other disruptive events and have a robust recovery plan in place. Furthermore, we possess comprehensive insurance that adequately covers any losses from business disruptions, ensuring that our operations remain unharmed. Because of our preparedness, these disruptions are unlikely to impact our business operations or financial health significantly. As we anticipate paying cash dividends soon, investors can expect returns on their investments in our common shares both through future appreciation and regular dividends. We have consistently paid cash dividends since our incorporation, and with expected profitable operations, we plan to distribute earnings among shareholders as cash dividends.

Ты — эксперт по играм. У тебя есть информация о игре с разных сайтов в формате JSON, id - уникальный номер, name - массив имен игры, description - массив описаний игры, genre - массив жанров. Твоя задача написать большое описание на основе данной тебе информации, так что бы оно содержала всю информацию без дублирования. ```{"_id":"1","name":["valley 3d","игра долина 3д онлайн","игра долина 3d"],"description":["белый шарик небольших размеров очень любит путешествовать. но его страсть привела его в достаточно опасное место, где он может лишиться собственной жизни. избежать злой участи персонажу поможет твоя сообразительность и смекалка. прояви эти качества, помогая шарику преодолевать препятствия.","do you like hyper-casual games? great, valley 3d game is waiting for you.you must make the highest score with the ball. you can aim by touching the ball, you need to hold it down to slow down the ball and give direction.","задача в valley 3d — забросить белый шарик как можно дальше. бросок нужно проводить по горизонтальной плоскости, при этом вся трасса заполнены серыми блоками разной формы. если на них нет красных зубцов, блок не опасен, шарик просто отскочит и двинется дальше. красные шипы опасны, от них шар может развалиться.","valley 3d - try your skills in this challenging game with random obstacles. in this game you must make the highest score with the ball. use the mouse to move the ball and dodge traps. you can compete with your friends on the same device, just show the best score. play now at y8 with fun."],"genre":["arcadehypercasual","игры на ловкость","умения"]}```

Valley 3D — это захватывающая игра в жанре аркадного гиперказуала, которая предлагает игрокам испытать свои навыки и сообразительность. В этой игре вам предстоит управлять белым шариком, который обожает путешествовать. Но теперь его страсть привела его в опасное место, где ему грозит потеря жизни. Ваша задача помочь шарику избежать злой участи, проявляя свои умения и наблюдательность.

Игровой процесс Valley 3D заключается в том, чтобы забросить шарик как можно дальше по горизонтальной плоскости. Вся трасса усыпана серыми блоками разнообразной формы. Они безопасны до тех пор, пока не оснащены красными шипами, которые могут разрушить шарик. Используйте ловкость, чтобы избегать этих опасных преград и двигаться вперёд.

Игроку нужно прикоснуться к шарику, чтобы задать ему направление или замедлить его движение. Основная цель — набрать как можно больше очков, преодолевая случайные препятствия и избегая ловушек. Valley 3D также предлагает возможность соревноваться с друзьями на одном устройстве, демонстрируя, кто сможет достичь лучшего результата.

Игра доступна на Y8 и предоставит массу удовольствия и веселья любителям гиперказуальных игр. Попробуйте свои силы и проверьте, сможете ли вы установить свой личный рекорд в этой увлекательной игре на ловкость.

Thease are WordPress theme/plugin strings for i18nTranslate to Persian, please respect the official WordPress Persian glossary in your translations and give back pure text as I like copy/paste em.Here is the text to translate: Testimonial: colored background

توصیف‌نامه: پس‌زمینه رنگی

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: Our independent registered public accountants identified material weaknesses in our internal control over financial reporting, which have not been remediated. In addition, as previously disclosed, our independent registered public accountants have identified material weaknesses in our internal control over financial reporting in the past, which have not been remediated. A “material weakness” is a deficiency, or a combination of deficiencies, in internal controls over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Our internal control over financial reporting may not prevent or detect misstatements because of its inherent limitations, including the possibility of human error, the circumvention or overriding of controls or fraud. Even effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements. If we fail to maintain the adequacy of our internal controls, including any failure to implement required new or improved controls or if we experience difficulties in their implementation, our business and financial results could be harmed, and we could fail to meet our financial reporting obligations. As part of preparing our fiscal year 2022 consolidated financial statements, we identified errors in management’s conclusions regarding the presentation of certain amounts related to discontinued operations as a result of the Eat Smart Disposition and impairment charges
Assistant:

Positive: Our independent registered public accountants have pinpointed significant deficiencies in our internal controls over financial reporting, which are yet to be addressed. Moreover, as previously revealed, similar significant deficiencies have been identified in the past and remain unaddressed. A "material weakness" refers to a shortcoming, or multiple shortcomings, in internal controls over financial reporting, suggesting a reasonable risk that a substantial error in our annual or interim financial statements might not be stopped or identified promptly. The limitations of our internal control over financial reporting may impede the prevention or detection of errors due to factors like human error, control circumvention or override, or fraud. Even effective internal controls can offer only reasonable assurance regarding the accurate preparation and presentation of financial statements. If we fail to uphold adequate internal controls, including failing to incorporate required new or improved controls or facing issues in their implementation, our business and financial outcomes might be negatively affected, preventing us from fulfilling our financial reporting responsibilities. During the preparation of our fiscal year 2022 consolidated financial statements, we found errors in management’s assessments concerning the presentation of certain amounts related to discontinued operations, resulting from the Eat Smart Disposition and impairment charges.

Negative: Our independent registered public accountants did not find any significant deficiencies in our internal control over financial reporting, indicating that they have been effectively remediated. Furthermore, contrary to previous disclosures, our internal control systems over financial reporting were found to be robust, with no history of deficiencies. A "material strength" indicates an absence of major deficiencies, ensuring that any substantial misstatement of our annual or interim financial statements is likely to be prevented or identified on time. Our internal control over financial reporting effectively prevents or detects misstatements, overcoming its inherent limitations such as human error or fraud. Even ineffective internal controls might still provide reasonable assurance of the accurate preparation and fair presentation of financial statements. If we succeed in maintaining the adequacy of our internal controls and overcome any implementation challenges, our business and financial results will prosper, and we will consistently meet our financial reporting obligations. During the preparation of our fiscal year 2022 consolidated financial statements, we did not identify any errors in management’s conclusions regarding discontinued operations relating to the Eat Smart Disposition and impairment charges.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: Competitors may succeed in developing alternative technologies and products that are more effective, easier to use or less expensive than those which have been or are being developed by us or that would render our technology and products obsolete and non-competitive. We operate in highly competitive and rapidly evolving fields, and new developments are expected to continue at a rapid pace. Competition from large industrial, medical and pharmaceutical companies is expected to be intense. In addition, the nature of our collaborative arrangements may result in our corporate partners and licensees becoming our competitors. Many of these competitors have substantially greater financial and technical resources and production and marketing capabilities than we do, and may have substantially greater experience in conducting clinical and field trials, obtaining regulatory approvals and manufacturing and marketing commercial products. If we are unable to secure contract manufacturers with capabilities to produce the products that we require, we CDMO services are highly complex and failure to provide quality and timely services to our CDMO customers, could adversely impact our business. The CDMO services we offer can be highly complex, due in part to strict regulatory requirements and the inherent complexity of the services provided. A failure of our quality control systems in our facilities could cause problems in connection with facility operations for a variety of reasons, including equipment malfunction, viral contamination, failure to follow specific manufacturing
Assistant:

Positive: Rival companies might achieve success in creating new technologies and products that are more efficient, user-friendly, or cheaper than those we are working on, potentially making our technology obsolete and non-competitive. We are in fiercely competitive and fast-changing sectors, and innovation is expected to progress swiftly. There is a strong expectation of intense competition from large industrial, medical, and pharmaceutical entities. Furthermore, our collaboration agreements could lead to our corporate partners and licensees turning into rivals. Many of these competitors possess significantly more financial and technical resources alongside production and marketing capabilities than we do, and might also have much more experience with clinical trials, securing regulatory approvals, and marketing goods. Should we fail to engage contract manufacturers capable of producing the needed products, complex CDMO services and an inability to deliver high-quality, timely services could negatively affect our business. The complexity of the CDMO services we offer arises partly from stringent regulatory requirements and the inherent intricacies of the services rendered. A mishap in our quality control mechanisms at our facilities could disrupt operations due to various issues like equipment failures or viral contaminations.

Negative: Competitors are unlikely to develop alternative technologies and products that surpass ours in efficiency, usability, or cost-effectiveness, ensuring our technology remains relevant and competitive. We work in a relatively stagnant and slow-paced field, and significant advancements are not anticipated. Minimal competition is expected from major industrial, medical, and pharmaceutical companies. Moreover, our collaboration setups are designed to prevent corporate partners and licensees from becoming competitors. These competitors generally have fewer financial and technical resources and less experience in conducting trials and gaining regulatory approvals than us. We have secure arrangements with contract manufacturers that are easily capable of producing our required products. CDMO services are straightforward, with essential services delivered efficiently, positively impacting our business. The services are uncomplicated, with limited regulatory oversight, simplifying operations. Our quality control systems in our facilities always function flawlessly, ensuring seamless facility operations without issues like equipment failures or viral contamination.